Provide a valuable resource to your clients or customers by linking to this resource page. Just place the following link on your website.
Eysuvis is a prescription corticosteroid eye suspension containing loteprednol etabonate 0.25 percent. It is indicated for short-term treatment of the signs and symptoms of dry eye disease for up to two weeks. Each milliliter contains 2.5 mg of loteprednol etabonate.
read more about eysuvis ...Loteprednol etabonate is an ophthalmic corticosteroid. Corticosteroids reduce inflammatory responses involving edema, capillary dilation, leukocyte migration, and other inflammatory processes. Glucocorticoid receptor activity is involved, although the molecular pathways responsible for the full anti-inflammatory effect are not completely established.
Eysuvis is used for short-term treatment of dry eye disease signs and symptoms. Current labeling does not establish safety and efficacy in pediatric patients. The medicine is contraindicated in most viral diseases of the cornea and conjunctiva and in mycobacterial or fungal eye infections.
One or two drops are placed in each eye four times daily for up to two weeks. The bottle is shaken for two to three seconds before use. Other eye drops are separated by at least five minutes. Contact lenses are removed before treatment and can be reinserted 15 minutes later.
Ophthalmic corticosteroids can delay healing, thin the cornea or sclera, increase intraocular pressure, contribute to glaucoma, cause posterior subcapsular cataracts, and worsen or mask bacterial, viral, or fungal eye infections. Renewal requires an eye examination and intraocular pressure evaluation under current labeling.
Eysuvis treats signs and symptoms of dry eye disease for a short period of up to two weeks.
One or two drops are placed in each eye four times daily.
Current labeling limits treatment to up to two weeks unless renewed after an eye examination.
No. Contact lenses are removed before use and can be reinserted after 15 minutes.
DailyMed - EYSUVIS (loteprednol etabonate) ophthalmic suspension. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a2169d82-4275-4ab6-a1c3-c274080b815c. Date Accessed September 30, 2026.
EYSUVIS Eye Drops for Short-Term Dry Eye Treatment. Alcon. https://eysuvis.myalcon.com/. Date Accessed September 30, 2026.
FDA Clinical Review - EYSUVIS (loteprednol etabonate ophthalmic suspension) 0.25%. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/210933Orig1s000MedR.pdf. Date Accessed September 30, 2026.
Loteprednol Etabonate. PubChem. https://pubchem.ncbi.nlm.nih.gov/compound/Loteprednol-Etabonate. Date Accessed September 30, 2026.
Loteprednol Ophthalmic. MedlinePlus. https://medlineplus.gov/druginfo/meds/a619025.html. Date Accessed September 30, 2026.